CBER Director Peter Marks has been delegated the authority to decide if Pepaxto should remain on the market. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, FDA images
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
